Literature DB >> 292536

Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.

P J Kearney, P A Light, A Preece, M G Mott.   

Abstract

Serum methotrexate levels were measured for 5 h after oral intake in 11 children with acute lymphoblastic leukaemia. The curves obtained with the child's regular dose of methotrexate varied widely, and were independent of the doses used. Peak levels were found in samples taken up to 3h after ingestion, and ranged from 300 to 1250 ng/ml. In the doses used, methotrexate toxicity was present in one of the eleven children, and was associated with a delayed peak and a high 5-h methotrexate level. Individual drug metabolism could be an important factor in the response to treatment, and needs to be evaluated in the assessment of protocols.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 292536     DOI: 10.1007/bf00254982

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  The current status of the treatment of childhood acute lymphoblastic leukemia.

Authors:  A M Mauer; J V Simone
Journal:  Cancer Treat Rev       Date:  1976-03       Impact factor: 12.111

2.  Effect of route of administration and effusions on methotrexate pharmacokinetics.

Authors:  S H Wan; D H Huffman; D L Azarnoff; R Stephens; B Hoogstraten
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

3.  Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol).

Authors:  M Haghbin; C C Tan; B D Clarkson; V Miké; J H Burchenal; M L Murphy
Journal:  Cancer       Date:  1974-06       Impact factor: 6.860

4.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Drug dosage and remission duration in childhood lymphocytic leukemia.

Authors:  D Pinkel; K Hernandez; L Borella; C Holton; R Aur; G Samoy; C Pratt
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

6.  Acute leukaemia 1959-64: factors affecting prognosis.

Authors:  R M Hardisty; M M Till
Journal:  Arch Dis Child       Date:  1968-02       Impact factor: 3.791

7.  Treatment of acute lymphoblastic leukaemia: effect of "prophylactic" therapy against central nervous system leukaemia. Report ot the Medical Research Council by the Leukaemia Committee and the Working Party on Leukaemia in Childhood.

Authors: 
Journal:  Br Med J       Date:  1973-05-19

8.  Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia.

Authors:  A W Craft; H Kay; D N Lawson; T J McElwain
Journal:  Br Med J       Date:  1977-12-10

9.  Analysis of treatment of childhood leukaemia. V. Advantage of reduced chemotherapy during and immediately after cranial irradiation.

Authors:  I C MacLennan; J Peto; H E Kay
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

10.  Development and application of a radioimmunoassay for methotrexate.

Authors:  G W Aherne; E M Piall; V Marks
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

View more
  20 in total

1.  Sheffield, 28 and 29 march 1980.

Authors: 
Journal:  Arch Dis Child       Date:  1980-10       Impact factor: 3.791

2.  Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.

Authors:  Peter D Cole; Richard A Drachtman; Angela K Smith; Sarah Cate; Richard A Larson; Douglas S Hawkins; John Holcenberg; Kara Kelly; Barton A Kamen
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

Review 3.  Clinical pharmacokinetics of methotrexate in children.

Authors:  Y M Wang; T Fujimoto
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

4.  Enterotoxic effect of methotrexate: does it influence the drug's absorption in children with acute lymphoblastic leukaemia?

Authors:  C R Pinkerton; J F Glasgow; J M Bridges; S G Welshman
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-18

5.  Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.

Authors:  A D Pearson; S Mills; H A Amineddine; D R Long; A W Craft; J M Chessells
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.

Authors:  P Sonneveld; F W Schultz; K Nooter; K Hählen
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Adipose-derived stem cells retain their regenerative potential after methotrexate treatment.

Authors:  Olivia S Beane; Vera C Fonseca; Eric M Darling
Journal:  Exp Cell Res       Date:  2014-06-30       Impact factor: 3.905

8.  Medical Research Council leukaemia trial, UKALL VII. A report to the Council by the Working Party on Leukaemia in Childhood.

Authors: 
Journal:  Arch Dis Child       Date:  1985-11       Impact factor: 3.791

9.  Modification of oral methotrexate absorption in children with leukemia.

Authors:  M J Mahony; M S Murphy; J Wadsworth; M G Mott
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

10.  Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia.

Authors:  A D Pearson; A W Craft; E J Eastham; G W Aherne; P Littleton; G L Pearson; A N Campbell
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.